Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • A83 01 br Dickson RB Lippman ME Estrogenic

    2020-08-18


    [25] Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987;8:29–43. [26] Horie K, Urano T, Ikeda K, Inoue S. Estrogen-responsive RING finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 2003;85:101–4. [27] Dickson RB, Huff KK, Spencer EM, Lippman ME. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986;118:138–42.
    [35] Samanta S, Sharma VM, Khan A, Mercurio AM. Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 2012;31:4689–97. [36] Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane in-tracellular estrogen receptor mediates rapid cell signaling. Science 2005;307: 1625–30.
    [37] Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Morris JF, Prossnitz ER, et al. Expres-sion of G protein-coupled receptor-30, a G protein-coupled membrane estrogen re-ceptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology 2007;148:5842–50.
    [38] Meyerson NR, Zhou L, Guo YR, Zhao C, Tao YJ, Krug RM, et al. Nuclear TRIM25 spe-cifically targets influenza virus ribonucleoproteins to block the onset of RNA chain elongation. Cell Host Microbe 2017;22 (627–638 e7). [39] Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, et al. 14-3-3sigma in en-dometrial cancer–a possible prognostic marker in early-stage cancer. Clin Cancer Res 2005;11:7384–91. [40] Sun N, Xue Y, Dai T, Li X, Zheng N. Tripartite motif containing 25 promotes prolifer-ation and invasion of colorectal cancer A83 01 through TGF-beta signaling. Biosci Rep 2017;37. [41] Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z. IMP3, a pro-posed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol 2011;19:413–6. [42] Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel bio-marker for triple negative invasive mammary carcinoma associated with a more ag-gressive phenotype. Hum Pathol 2009;40:1528–33.
    Contents lists available at ScienceDirect
    Archives of Oral Biology
    journal homepage: www.elsevier.com/locate/archoralbio
    Blockade of peripheral endothelin receptors abolishes heat hyperalgesia and T spontaneous nociceptive behavior in a rat model of facial cancer
    Caroline Machado Kopruszinskia, ,1, Renata Cristiane dos Reisa, Giles Alexander Raeb, Juliana Geremias Chichorroa
    a Department of Pharmacology, Biological Sciences Section, Federal University of Parana, Curitiba, Brazil
    b Department of Pharmacology, Biological Sciences Center, Federal University of Santa, Catarina, Florianopolis, Brazil
    Keywords:
    Walker-256 tumor cells
    Evoked nociception
    Facial grooming
    Endothelins ETA receptor ETB receptor 
    Objective: To improve understanding of the pathophysiology of cancer-induced facial nociception, by evaluating the contribution of peripheral endothelin receptors in tumor-induced facial heat hyperalgesia, increased spon-taneous grooming, as well as ongoing nociception in a rat model of facial cancer.
    Design: The study was conducted using 396 rats. Facial cancer was induced by inoculating a suspension of Walker-256 cells into the rats’ right vibrissal pad. Facial heat hyperalgesia and spontaneous grooming were assessed on day 6, while the A83 01 conditioned place preference (CPP) test was performed on days 3–6 after tumor cells inoculation. Rats received local injections of the non-peptidic dual ETA/ETB endothelin receptors antagonist, bosentan (10 and 30 μg/50 μL), single or combined injections of peptidic ETA and ETB endothelin receptors antagonists (BQ-123 and BQ-788, at 20 ug/50 μL, each), or of lidocaine (1 mg/50 μl) and morphine (30 μg/ 50 μL).
    Results: Bosentan, lidocaine and morphine local treatment all attenuated tumor-induced heat hyperalgesia (p < 0.05) and spontaneous facial grooming (p < 0.05). However, BQ-123 and BQ-788 did not modify tumor-induced heat hyperalgesia or the spontaneous facial grooming (p > 0.05). Whether this difference in effec-tiveness is due to receptor affinity or to pharmacokinetic factors still needs to be explored. Local injection of bosentan, lidocaine or morphine failed to control ongoing nociception, as evidenced by the absence of CPP in tumor-bearing rats (p > 0.05).
    Conclusion: Endothelins, acting through peripheral ETA and ETB receptors, may play a significant role on the development of heat hyperalgesia and increased spontaneous grooming associated to facial cancer in rats.